Brain scan clues could predict which cancer patients will survive longer
NCT ID NCT03144167
Summary
This study aims to find early signs from brain scans that can predict whether patients with recurrent glioblastoma (an aggressive brain cancer) will survive at least 6 months while taking the drug bevacizumab (Avastin). Researchers will scan patients' brains shortly after starting treatment to look for chemical patterns linked to survival. The goal is to help identify which patients are most likely to benefit from this expensive medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Amiens Picardie
RECRUITINGAmiens, Picardie, 80054, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.